Lunella (Estradiol cypionate and Medroxyprogesterone acetate injectable) is commonly used to help with certain symptoms related to systemic imbalance, particularly concerning reproductive planning and associated menstrual health. The therapeutic domain for combined injectable contraceptives involves reproductive health management.

The medication is relevant for addressing the risk of unintended pregnancy, which is a key component of long-term family planning. It is relevant in situations where short-term symptomatic assistance is needed for reproductive health. This application provides support that helps ease the overall symptom burden related to the risk of unintended conception. This supports general well-being during symptomatic phases.

It is commonly used across conditions presenting with episodic or fluctuating manifestations, including systemic contraception, support for menstrual cycle regularity, and easing of cyclic physical discomfort (pain and cramps). The formulation is also relevant for managing symptoms that interfere with daily comfort. This generally contributes to improved comfort during periods of heightened symptoms.

“This application provides support that helps ease the overall symptom burden related to the risk of unintended conception.”

Quick Fact: Supportive Management for Cyclic Discomfort Lunella supports the management of symptoms related to systemic imbalance, generally contributing to improved comfort during periods of heightened symptoms. This supports patients during difficult episodes by easing distress.

Regulatory References

1. WHO Essential Medicines List review for Combined Injectable Contraceptives

Lunella (Estradiol cypionate and Medroxyprogesterone acetate injectable suspension) is officially indicated for use by women of reproductive age for the prevention of pregnancy. Eligibility is strictly defined by regulatory documents, which establish specific criteria for who may and may not use the medicine.

Eligibility Classification	Population Status	Restrictions & Rules
Populations Contraindicated	Absolute Non-Eligibility	Pregnancy (known or suspected), Thromboembolic Disorders (current or past history), Cerebral or Coronary Artery Disease, Significant Liver Disease, Known or Suspected Breast Cancer or other estrogen-dependent neoplasia, and Undiagnosed Abnormal Genital Bleeding.
Use Not Recommended/Limited	Conditional/Restricted Use	Long-term use (i.e., longer than 2 years) is not recommended unless alternative methods are inadequate. Use is not indicated before menarche (first menstrual period). Heavy smokers aged 35 or older face a significant cardiovascular risk, making use generally prohibited.
Physiological/Comorbidity Status	Specific Limitations	Use must be discontinued before and after periods of prolonged immobilization or major surgery. Initiation for breastfeeding women is not recommended until at least six weeks postpartum.

The interaction profile for Lunella is defined by pharmacokinetic changes that modify the exposure of the hormonal components or co-administered medications, as documented in official regulatory labeling.

Interactions with Enzyme Inducers

The contraceptive effectiveness of Lunella may be reduced when co-administered with medicines or herbal products that increase the metabolism of its synthetic hormones. The Estradiol component is sensitive to changes involving the CYP3A4 enzyme. Officially documented interacting medicines classified as enzyme inducers include Rifampin, Carbamazepine, and Phenytoin. The herbal product St. John's Wort is also noted to reduce the circulating hormone levels. Furthermore, the drug Aminoglutethimide is specifically documented in regulatory labeling to significantly depress the serum concentrations of Medroxyprogesterone acetate (MPA), an outcome associated with a risk of decreased contraceptive efficacy.

Interactions Affecting Co-administered Drugs

Lunella itself is documented to affect the disposition of certain co-administered medications. Concomitant use may result in the increased plasma levels of drugs such as Cyclosporine, the corticosteroid Prednisolone, and Theophylline. This effect necessitates monitoring the concentration of these co-administered drugs. Additionally, co-administration with other hormonal contraceptives is generally restricted due to the cumulative hormone dose, which is associated with an elevated risk of thromboembolism.

How Lunella Works

Lunella's mechanism of action involves two primary mechanistic domains that influence its physiological consequences. The drug's activity stems from its specific interaction with key inhibitory signaling pathways in the Central Nervous System (CNS), which contributes to a reduction in overall neural excitability.

Lunella acts by positively modulating specific sites on the GABA-A receptor complexes, which are the main targets for inhibitory signals in the CNS. This binding does not activate the receptor directly but rather enhances the receptor's sensitivity to the natural inhibitory neurotransmitter GABA (gamma-aminobutyric acid). This mechanistic domain results in a reduction of neuronal firing and CNS activity.

By amplifying the inhibitory signal at the GABA-A receptor, Lunella increases the movement of chloride ions into the neuron. This mechanistic cascade hyperpolarizes the nerve cell, which consequently reduces its excitability and slows the transmission of nerve impulses across the CNS. This action on the inhibitory pathway results in the physiological changes of decreased neural alertness and the initiation of the sleep state.

Administration Scope

Lunella is administered as a 0.5 mL unit dose via intramuscular (IM) injection. This standardized volume contains 25 mg of Medroxyprogesterone acetate and 5 mg of Estradiol cypionate. As an injectable suspension, the medication must be vigorously shaken by the health-care professional immediately prior to administration to ensure a uniform dose. The first dose is typically initiated within the first five days after the start of a menstrual period to establish the cycle.

Dosing Frequency and Procedural Rules

The core of the usage pattern is a rigid monthly schedule, with subsequent doses required every 28 to 30 days to maintain its effect. The safety and effectiveness of this regimen are established in postpubertal adolescents, though its use is not indicated before menarche. If the interval between injections is delayed and exceeds 33 days, the protocol requires that a pregnancy test must be administered by the health-care professional before the next dose is given, aligning with established instructions for managing a missed schedule.

Connection to the Overall Use Protocol

The prescribed instructions establish a highly specific, standardized protocol, focusing on the correct intramuscular delivery of a fixed unit dose by a professional. This administration procedure is strictly bound to a precise monthly schedule and an initial cycle timing requirement to ensure the drug is used exactly as defined in the standardized protocol. The protocol explicitly outlines the mandatory steps for dose preparation and the necessary criteria for administering the injection after a missed interval.

Research evidence / Overview of studies for Lunella

Evidence for Use in Systemic Contraception (Pregnancy Prevention)

The research on Lunella has primarily focused on research exploring systemic contraception in healthy women of reproductive age. This evaluation was performed through large-scale clinical trials and specific pharmacodynamic (PD) studies conducted as part of the overall research program.

Researchers examined key outcomes related to to assess its role in pregnancy prevention. These studies monitored the rate of unintended pregnancy using established measures, such as the Pearl Index, to describe group patterns observed in the studies. Furthermore, research monitored changes in key hormonal biomarkers related to ovarian activity. Studies monitored suppression of ovulation, as shown by measured changes in serum progesterone levels, a key physiological measure. Findings describe patterns observed in the studies.

Research on Menstrual Cycle Control and Regulation

Lunella was also evaluated in studies examining patient-reported experiences related to menstrual bleeding patterns, an area of study in combined hormonal contraception research. Comparative clinical trials were used to monitor outcomes related to physical discomfort and systemic or functional imbalance. Trials described that patterns, such as initial irregular bleeding, showed patterns of change over the first few months of use. Data relies heavily on patient self-reported diaries, and the clinical significance of varied bleeding patterns remains uncertain and is defined differently across the evidence landscape.

Long-Term Studies and Research Gaps

Dedicated studies focused on the return of ovarian function after the medicine is discontinued. These studies monitored the time required for a key biomarker, the progesterone level, to return to levels associated with ovarian activity. Findings describe group patterns related to the average and range of time required for the biochemical marker to return.

A key limitation is that these studies focus specifically on the return of the hormonal marker (ovulation), rather than actual outcomes like time to conception or pregnancy itself. Long-term effects are not fully established, as the duration of follow-up in the primary trials was typically limited to about one year. Findings describe group patterns, not individualized outcomes, and research describes what has been explored and what remains to be studied.

Common questions about Lunella (FAQ)

Q: What is the difference between Lunella and [similar drug X]?

Lunella is the brand name given to the specific combination injectable contraceptive that contains the two synthetic hormones, Medroxyprogesterone acetate and Estradiol cypionate. According to official classification, this specific combination is categorized as a Combined Injectable Contraceptive (CIC).

This composition defines the medicine’s pharmacological class and distinguishes it from single-hormone contraceptives or other drug classes.

Q: Is Lunella an opioid or a sedative?

Lunella is classified in regulatory documents as a systemic sex-hormonal preparation used for contraception; it is not an opioid. Research evidence indicates that the drug’s mechanism involves modulating the GABA-A receptor in the brain, which is the same pathway influenced by some sedating medications, leading to a reduction in neural activity.

Q: Can Lunella affect sleep patterns or cause insomnia?

Official product information indicates that common side effects include nervousness and dizziness, which are central nervous system (CNS) effects. While the drug affects the central nervous system, specific sleep disturbances like insomnia are not typically listed among the most frequently observed adverse reactions.

If unexpected or persistent symptoms are experienced, consultation with a health professional is necessary.

Q: Is Lunella available in different strengths?

According to official product labeling, Lunella is supplied only as a single fixed-unit dose injection. This unit dose contains a standard amount: 25 mg of Medroxyprogesterone acetate and 5 mg of Estradiol cypionate.

The safety and effectiveness are established based on this specific formulation and strength.

Q: Do older adults react differently to Lunella?

Lunella is officially indicated for women of reproductive age. Regulatory documentation places specific restrictions on its use in older women, particularly those aged 35 years or older who are heavy smokers, due to a significantly increased risk of serious cardiovascular events.

This restriction indicates that age and lifestyle factors can modify the risk profile.

Q: Can Lunella be crushed or split?

No, Lunella is an injectable suspension that is administered into the muscle by a trained healthcare professional. It is not provided in a form that can be crushed, split, or taken orally.

The method of delivery is a strict component of the use conditions defined in official instructions.

Q: Is Lunella associated with any mood changes or depression?

Official prescribing information acknowledges that psychiatric disorders, including nervousness, anxiety, and depression, have been reported as possible adverse reactions associated with hormonal contraceptives. Persistent changes in mood or emotional state may require reporting to a healthcare provider.

Q: Can someone take Lunella if they have a history of seizures?

The drug's components, particularly the progestin, have been researched in women with epilepsy, with studies examining the drug's effectiveness when used alongside certain anti-epileptic medications. This indicates that individualized guidance and assessment beyond the general label information is necessary for use.

Q: Does Lunella have a generic name available?

Lunella is a brand name. The medicine's active components are described by their generic names: Medroxyprogesterone acetate and Estradiol cypionate.

These names are used globally to describe the synthetic hormones contained in the formulation.

Q: How quickly can someone expect Lunella to start working?

The time it takes for contraceptive protection to start depends on when the first injection is given during the menstrual cycle. Regulatory instructions state that contraceptive protection is considered established immediately if the first dose is administered within the first five days of a menstrual period.

If given later in the cycle, protection may take up to seven days to establish.

Q: What is the half-life of Lunella?

Pharmacokinetic studies describe the half-life, which is the time it takes for half of the drug to be eliminated from the body. The apparent elimination half-life for the Medroxyprogesterone acetate component is typically 14-17 days, and the half-life for the Estradiol cypionate component is reported to be 8-10 days.

Q: Can Lunella pass into breast milk?

Yes, studies show that both the active hormonal components of Lunella can pass into breast milk. Official prescribing information indicates that use in women who are breastfeeding is restricted until at least six weeks postpartum.

Q: Is Lunella known to interact with caffeine?

Official information recognizes a potential interaction between the drug's components and caffeine. This interaction may result in an increased risk of certain side effects.

Concerns regarding co-consumption of caffeine while on the medicine typically require professional discussion.

Q: Is it true that Lunella can cause blurry vision?

Changes in vision, which may include blurry vision, have been reported as adverse effects of the drug. According to regulatory warnings, changes to vision can be a sign of a potentially serious condition.

If this occurs, the official guidance is that immediate reporting to a healthcare professional is necessary.

Q: Does Lunella affect the results of any common lab tests?

Official product labeling indicates that Lunella may interfere with the accuracy of certain laboratory test results. This interference can specifically affect tests that measure bodily factors such as clotting proteins and lipid (fat) levels.

Q: What is the highest studied dosage of Lunella in clinical trials?

The clinical research and the approved product utilize a standard fixed unit dose. The dosage studied in clinical trials for contraceptive efficacy is the 25 mg Medroxyprogesterone acetate and 5 mg Estradiol cypionate fixed unit dose.

This is the only approved dose for systemic contraception.

How to Store and Dispose of Lunella?

The storage and disposal instructions for Lunella (Estradiol cypionate and Medroxyprogesterone acetate injectable suspension) are governed by official regulatory requirements.

Condition	Requirement
Storage Temperature	Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Container Rule	Keep the container tightly closed and store as directed by the product packaging.
Child Safety	Must be kept out of the sight and reach of children.
Disposal	Dispose of the contents and container according to all applicable local and national regulations for pharmaceutical waste.

The product must be prevented from entering the environment, with specific instructions to not allow disposal into sewers, surface water, or ground water. Due to the nature of the injectable suspension, storage and handling are typically managed by a healthcare professional.